BiotechTube

LY3361237 + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Systemic Lupus Erythematosus

Conditions

Systemic Lupus Erythematosus

Trial Timeline

Mar 7, 2022 → Dec 29, 2023

NCT ID
NCT05123586

About LY3361237 + Placebo

LY3361237 + Placebo is a phase 2 stage product being developed by Eli Lilly for Systemic Lupus Erythematosus. The current trial status is terminated. This product is registered under clinical trial identifier NCT05123586. Target conditions include Systemic Lupus Erythematosus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT05123586Phase 2Terminated
NCT04975295Phase 1Completed
NCT03933943Phase 1Completed

Competing Products

20 competing products in Systemic Lupus Erythematosus

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 2
52
E6742EisaiPhase 1/2
41
KHK4827Kyowa KirinPhase 1
33
KHK4827 + PlaceboKyowa KirinPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + CyclophosphamideEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85